Get the Stockscreener App
17.57
0.29%
0.05
After Hours:
17.57
Acadia Pharmaceuticals Inc stock is traded at $17.57, with a volume of 2.14M.
It is up +0.29% in the last 24 hours and up +0.92% over the past month.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
See More
Previous Close:
$17.52
Open:
$17.73
24h Volume:
2.14M
Relative Volume:
0.99
Market Cap:
$2.92B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
97.61
EPS:
0.18
Net Cash Flow:
$80.53M
1W Performance:
+1.80%
1M Performance:
+0.92%
6M Performance:
-4.25%
1Y Performance:
-37.21%
1-Day Range:
$17.35
$17.89
1-Week Range:
$16.61
$18.23
52-Week Range:
$14.15
$29.29
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
17.57 | 2.92B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-12-24 | Reiterated | Needham | Buy |
| Jan-30-24 | Initiated | Robert W. Baird | Outperform |
| Jan-24-24 | Upgrade | Needham | Hold → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
| Oct-17-23 | Initiated | UBS | Buy |
| Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
| Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Jun-10-21 | Initiated | Berenberg | Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
| Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-21 | Downgrade | Stifel | Buy → Hold |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Initiated | Morgan Stanley | Overweight |
| Jul-07-20 | Upgrade | Stifel | Hold → Buy |
| Apr-16-20 | Initiated | Jefferies | Buy |
| Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Dec-16-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-23-19 | Reiterated | Needham | Buy |
| Dec-10-18 | Initiated | Canaccord Genuity | Hold |
| Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-09-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Initiated | Stifel | Hold |
| Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals - MSN
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Down 6.9%Time to Sell? - MarketBeat
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
JPM25: After taking the wheel at Acadia, CEO Catherine Owen Adams looks to steer firm toward $1B in sales - FiercePharma
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised) - MSN
Burney Co. Purchases New Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Neuren partner submits Rett drug for EU approval - NT News
Acadia Pharmaceuticals: Billion-Dollar Milestone and Global Expansion in 2025 - GuruFocus.com
ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Down 6.9%Time to Sell? - MarketBeat
Acadia expects more than $1B in sales for 2025 - MSN
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome - Agenzia ANSA
Acadia seeks EMA nod for first Rett syndrome therapy - Investing.com India
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference - The Bakersfield Californian
Acadia Pharma Targets $1B Sales Milestone in 2025, Expands DAYBUE to European Market - StockTitan
Acadia Pharma (ACAD) Submits Marketing Authorization Application to the EMA for Trofinetide for the Treatment of Rett Syndrome - StreetInsider.com
Acadia Seeks EU Approval for Breakthrough Rett Syndrome Drug Trofinetide After Phase 3 Success - StockTitan
(ACAD) Proactive Strategies - Stock Traders Daily
Is ACADIA Pharmaceuticals (ACAD) the Best Medical Stock to Buy Under $20? - Insider Monkey
12 Best Medical Stocks To Buy Under $20 - Insider Monkey
Further weakness as ACADIA Pharmaceuticals (NASDAQ:ACAD) drops 5.2% this week, taking five-year losses to 61% - Yahoo Finance
Why Investors Shouldn't Be Surprised By ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Low P/S - Simply Wall St
Acadia Pharmaceuticals downgraded to Neutral from Buy at Guggenheim - MSN
Principal Financial Group Inc. Increases Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World
ACADIA Pharmaceuticals (NASDAQ:ACAD) Downgraded to “Neutral” Rating by Guggenheim - Defense World
ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Gap DownHere's What Happened - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Downgraded to Neutral Rating by Guggenheim - MarketBeat
Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues - MSN
ACADIA Pharmaceuticals Inc.(NasdaqGS: ACAD) added to S&P 600 Health Care - Marketscreener.com
(ACAD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
ACADIA Pharmaceuticals (NASDAQ:ACAD) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Why ACADIA Pharmaceuticals Inc. (ACAD) Is Skyrocketing - Insider Monkey
Acadia Pharma (ACAD) 5400 contracts of February 19 calls trade - StreetInsider.com
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide - Benzinga
Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet - Benzinga
Acadia Pharmaceuticals, FTAI Aviation And Other Big Stocks Moving Higher On Tuesday - Benzinga
ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Gap UpHere's What Happened - MarketBeat
Acadia Pharmaceuticals Shares Rise With Co to Join S&P SmallCap 600 - MarketWatch
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock - Yahoo Finance
Short Interest in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Decreases By 5.5% - Defense World
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Large Decrease in Short Interest - MarketBeat
Acadia Pharma (ACAD) to Join S&P SmallCap 600 - StreetInsider.com
Acadia Pharmaceuticals Set to Join S&P SmallCap 600 - Yahoo Finance
3 Specialty Pharma Stocks Addressing Unmet Medical Needs - Inkl
NBIX: 3 Specialty Pharma Stocks Addressing Unmet Medical Needs - StockNews.com
Acadia presents preclinical characterization of ACP-204 - BioWorld Online
Geode Capital Management LLC Has $44.23 Million Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):